EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
+50.75%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$492M
AUM Growth
+$492M
(+54%)
Cap. Flow
+$111M
Cap. Flow
% of AUM
22.65%
Top 10 Holdings %
Top 10 Hldgs %
53.05%
Holding
79
New
22
Increased
21
Reduced
20
Closed
8
Top Buys
| 1 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$20.3M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$14.7M |
| 3 |
Pennant Group
PNTG
|
$12.3M |
| 4 |
Sanofi
SNY
|
$10.1M |
| 5 |
MDCO
Medicines Co
MDCO
|
$9.71M |
Top Sells
| 1 |
AMRN
Amarin Corp
AMRN
|
$8.88M |
| 2 |
ZGNX
Zogenix, Inc.
ZGNX
|
$7.72M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$7.4M |
| 4 |
DexCom
DXCM
|
$7.11M |
| 5 |
ABMD
Abiomed Inc
ABMD
|
$5.33M |
Sector Composition
| 1 | Healthcare | 86.78% |
| 2 | Real Estate | 1.94% |
| 3 | Communication Services | 1.48% |
| 4 | Industrials | 1.1% |
| 5 | Financials | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
SPDR S&P 500 ETF Trust
SPY
$656B
| – | – |
0
| – | – |
|
77
CEL-SCI Corp
CVM
$81.4M
| – | – |
0
| – | – |
|
78
Codexis
CDXS
$218M
| – | – |
-63,000
| Closed | -$864K |
|
|
79
Alnylam Pharmaceuticals
ALNY
$58.6B
| – | – |
-92,040
| Closed | -$7.4M |
|